

FFF Enterprises Celebrates 21 Years of Industry Innovation

Biopharmaceuticals distributor makes innovation a priority by continually finding new ways to secure the supply chain and streamline delivery models for the critical-care products and vaccines it manages.

July 8, 2009



FFF Enterprises, Inc., the nation's largest and most trusted distributor of plasma products, vaccines and critical-care biopharmaceuticals, announced today that it is commemorating 21 counterfeit-free years, a significant accomplishment since the pharmaceutical supply chain has long been vulnerable to counterfeiting, price gouging and inferior management of fragile plasma derivatives and other specialty products. Thanks to FFF's innovative business model and commitment to "helping healthcare care," that supply chain is significantly safer today than it was two decades ago.

"We are creating a standard for safety and excellence that we hope will continue to have a positive influence on the industry as a whole," states Patrick M. Schmidt, chief executive officer, FFF Enterprises, Inc. "Our customers recognize the value of channel integrity to their patients and their bottom lines."

An industry leader, FFF has developed a number of innovative technologies that have been instrumental in transforming accepted industry protocols. The company's first-of-its-kind Verified Electronic Pedigree™ (VEP) system electronically displays the chain of custody for every product it ships, and its LotTrack™ service tracks products by lot number and provides recall notification to those affected. Another example of FFF's quality commitment is epitomized by its specialty pharmacy subsidiary, NuFACTOR, which was established to provide IVIG, coagulation factors and vaccines directly to patients. Other innovative programs include MyFluVaccine and VaxAmerica, which have provided revolutionary approaches to vaccination, streamlining access and administration to preventive vaccines for healthcare providers and patients.

Recognized as the most trusted distributor of biopharmaceuticals, plasma products and vaccines in the nation, FFF serves over 80% of U.S. hospitals and supplies the nation's leading non-acute care group purchasing organizations. With its emphasis on patient safety, FFF has incorporated from the bottom up what the pharmaceutical industry struggles to enact from the top down – a secure supply chain.

"Making healthcare affordable, accessible and safe is a commitment we take very seriously," Schmidt says. "By securing the supply chain and offering innovations in healthcare delivery models, we can be instrumental in setting new industry standards and achieving our mission of 'helping healthcare care.'"

Never content to rest on its laurels, FFF continues to find new ways of expanding its sphere of influence; this month the company will make its second foray into the publishing arena with the launch of its new trade magazine, BioSupply Trends Quarterly.

"This newest publishing endeavor comes in response to the positive feedback from our customers who have come to rely on our BioSupply Trends bi-weekly e-newsletter," says Schmidt. "We envision this magazine to be an expanded resource for up-to-date news, trends, perspectives and leading indicators."

About FFF Enterprises, Inc.

FFF Enterprises, Inc., a privately held corporation, is the largest and most trusted distributor of plasma ➤



products, vaccines and other biopharmaceuticals in the U.S. Founded in 1988, FFF is celebrating its 21st year with more than a billion dollars in annual sales and a flawless safety track record. FFF's Guaranteed Channel Integrity™ ensures that products are purchased only from the manufacturer and shipped only to healthcare providers, protecting patients and manufacturers from counterfeit risks and pricing irregularities inherent in secondary and gray market channels. FFF's proprietary technologies, Verified Electronic Pedigree™ and Lot-Track™, provide verification of this secure channel. FFF's MyFluVaccine (www.MyFluVaccine.com) has revolutionized the flu marketplace, offering a dedicated flu vaccine supply, delivered to customers on the date of their choosing, and offering certainty in a volatile market segment. FFF's ability to move rapidly in a dynamically changing marketplace allows the creation of new opportunities for customers through innovative vehicles for distribution.

